True Wealth Design’s Applied Therapeutics APLT Stock Holding History

True Wealth Design’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-59	Closed	-$19	–	2727
2025 Q2	$19	Buy	+59	New	+$23	﹤0.01%	2514
2024 Q4	–	Sell	-72	Closed	-$612	–	1360
2024 Q3	$612	Buy	+72	New	+$424	﹤0.01%	1062

Other funds holding APLT

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

True Wealth Design's APLT Position: Q3 2025 in Review

True Wealth Design sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 59 shares — an estimated $19 sold.

True Wealth Design first reported a position in APLT in Q3 2024 and held it in 2 quarters. The position peaked at $612 in Q3 2024. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.

True Wealth Design reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
True Wealth Design sold 59 Applied Therapeutics shares in Q3 2025, an estimated $19.
True Wealth Design first reported a position in Applied Therapeutics in Q3 2024 and held it in 2 quarters.
True Wealth Design's Applied Therapeutics position peaked at $612 in Q3 2024.
70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.